Clinical Trial Update: A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 study evaluating Janssen's ExPEC9V vaccine for the prevention of invasive extraintestinal pathoge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Expec Disease

Drugs mentioned

• ExPEC9V (9-valent ExPEC vaccine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | Phase 3 | Status: COMPLETED